NeoGenomics, Inc. (NEO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 105.88M USD | Liabilities, Current |
| Cash and equivalents | 145.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 175.41M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 27.14M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $105.88M | $145.54M | (m) | $175.41M | $27.14M | (m) |
| 2026-03-31 | (m) | $84.59M | $146.14M | (m) | $167.42M | $29.84M | (m) |
| 2025-12-31 | (m) | $88.30M | $159.62M | (m) | $159.24M | $28.57M | (m) |
| 2025-09-30 | (m) | $97.87M | $164.12M | (m) | $155.30M | $28.46M | (m) |
| 2025-06-30 | (m) | $100.12M | $154.72M | (m) | $153.13M | $34.17M | (m) |
| 2025-03-31 | (m) | $279.69M | $346.19M | (m) | $151.21M | $29.77M | (m) |
| 2024-12-31 | (m) | $301.24M | $367.01M | (m) | $150.54M | $26.75M | (m) |
| 2024-09-30 | (m) | $296.41M | $361.99M | (m) | $151.43M | $24.46M | (m) |
| 2024-06-30 | (m) | $289.96M | $355.08M | (m) | $146.58M | $23.21M | (m) |
| 2024-03-31 | (m) | $76.71M | $331.91M | (m) | $140.28M | $20.32M | (m) |
| 2023-12-31 | (m) | $96.30M | $342.49M | (m) | $131.23M | $24.16M | (m) |
| 2023-09-30 | (m) | $92.93M | $306.24M | (m) | $132.64M | $24.05M | (m) |
| 2023-06-30 | (m) | $94.85M | $289.07M | (m) | $125.42M | $24.95M | (m) |
| 2023-03-31 | (m) | $86.61M | $275.61M | (m) | $118.84M | $24.43M | (m) |
| 2022-12-31 | (m) | $89.93M | $263.18M | (m) | $119.71M | $24.28M | (m) |
| 2022-09-30 | (m) | $85.00M | $266.13M | (m) | $111.99M | $23.80M | (m) |
| 2022-06-30 | $577.23M | $82.67M | $283.64M | $182.32M | $111.28M | $21.86M | 6.98× |
| 2022-03-31 | $592.23M | $82.07M | $305.90M | $175.53M | $110.80M | $23.84M | 7.22× |
| 2021-12-31 | $627.52M | $87.23M | $316.83M | $198.56M | $112.13M | $23.39M | 7.19× |
| 2021-09-30 | $647.67M | $92.74M | $340.56M | $202.14M | $104.96M | $21.83M | 6.98× |
| 2021-06-30 | $678.03M | $99.13M | $368.80M | $202.95M | $106.28M | $21.38M | 6.84× |
| 2021-03-31 | $905.60M | $67.75M | $611.97M | $190.71M | $102.92M | $21.38M | 13.37× |
| 2020-12-31 | $403.10M | $73.18M | $228.71M | $67.55M | $106.84M | $29.53M | 5.51× |
| 2020-09-30 | $387.31M | $64.61M | $233.23M | $50.38M | $103.70M | $20.64M | 5.99× |
| 2020-06-30 | (m) | $61.70M | $295.28M | (m) | $87.77M | $21.63M | (m) |
| 2020-03-31 | (m) | $67.65M | $86.25M | (m) | $99.97M | $20.29M | (m) |
| 2019-12-31 | (m) | $63.90M | $173.02M | (m) | $94.24M | $14.40M | (m) |
| 2019-09-30 | (m) | $68.91M | $178.89M | (m) | $91.13M | $12.63M | (m) |
| 2019-06-30 | (m) | $59.16M | $167.44M | (m) | $89.99M | $8.73M | (m) |
| 2019-03-31 | (m) | $72.70M | $13.20M | (m) | $82.58M | $9.67M | (m) |
| 2018-12-31 | (m) | $60.92M | $9.81M | (m) | $76.92M | $8.65M | (m) |
| 2018-09-30 | (m) | $47.05M | $118.44M | (m) | $62.69M | $6.83M | (m) |
| 2018-06-30 | (m) | $47.97M | $9.44M | (m) | $60.77M | $6.90M | (m) |
| 2018-03-31 | (m) | $43.30M | $15.17M | (m) | $58.13M | $7.51M | (m) |
| 2017-12-31 | (m) | $35.06M | $12.82M | (m) | $60.43M | $7.47M | (m) |
| 2017-09-30 | (m) | $40.11M | $12.21M | (m) | $62.72M | $6.09M | (m) |
| 2017-06-30 | (m) | $35.20M | $10.93M | (m) | $61.75M | $5.46M | (m) |
| 2017-03-31 | (m) | $39.88M | $11.04M | (m) | $61.72M | $5.97M | (m) |
| 2016-12-31 | (m) | $38.11M | $12.53M | (m) | $55.51M | $6.25M | (m) |
| 2016-09-30 | (m) | $35.39M | $28.93M | (m) | $50.18M | $5.95M | (m) |
| 2016-06-30 | (m) | $34.95M | $21.79M | (m) | $53.51M | $5.54M | (m) |
| 2016-03-31 | (m) | $34.32M | $19.26M | (m) | $50.09M | $5.33M | (m) |
| 2015-12-31 | (m) | $40.06M | $23.42M | (m) | $48.94M | $5.11M | (m) |
| 2015-09-30 | (m) | $15.33M | $33.97M | (m) | $21.56M | $2.97M | (m) |
| 2015-06-30 | (m) | $15.13M | $32.95M | (m) | $21.13M | $3.42M | (m) |
| 2015-03-31 | (m) | $13.86M | $31.25M | (m) | $21.48M | $2.60M | (m) |
| 2014-12-31 | (m) | $14.62M | $33.69M | (m) | $20.48M | $2.62M | (m) |
| 2014-09-30 | (m) | $13.95M | $34.37M | (m) | $18.30M | $2.97M | (m) |
| 2014-06-30 | (m) | $15.23M | $5.02M | (m) | $18.80M | $2.62M | (m) |
| 2014-03-31 | (m) | $15.23M | $5.38M | (m) | $19.26M | $2.00M | (m) |
| 2013-12-31 | (m) | $14.32M | $4.83M | (m) | $18.65M | $2.30M | (m) |
| 2013-09-30 | (m) | $12.25M | $4.93M | (m) | $15.73M | $2.07M | (m) |
| 2013-06-30 | (m) | $12.06M | $4.64M | (m) | $16.00M | $1.74M | (m) |
| 2013-03-31 | (m) | $11.95M | $4.63M | (m) | $15.63M | $1.65M | (m) |
| 2012-12-31 | (m) | $17.76M | $1.87M | (m) | $14.03M | $1.86M | (m) |
| 2012-09-30 | (m) | $16.67M | $2.04M | (m) | $12.01M | $1.91M | (m) |
| 2012-06-30 | (m) | $15.10M | $2.57M | (m) | $11.33M | $1.53M | (m) |
| 2012-03-31 | (m) | $14.75M | $2.76M | (m) | $10.68M | $1.31M | (m) |
| 2011-12-31 | (m) | $11.44M | $2.63M | (m) | $7.89M | $1.20M | (m) |
| 2011-09-30 | (m) | $10.54M | $2.65M | (m) | $7.37M | $1.10M | (m) |
| 2011-06-30 | (m) | $10.11M | $2.63M | (m) | $7.16M | $1.08M | (m) |
| 2011-03-31 | (m) | (m) | $2.53M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $9.17M | $1.10M | (m) | $5.24M | $887.00K | (m) |
| 2010-09-30 | (m) | (m) | $1.55M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $2.18M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.63M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |